Head-To-Head Comparison: Biofrontera (NASDAQ:BFRI) & Unicycive Therapeutics (NASDAQ:UNCY)

Unicycive Therapeutics (NASDAQ:UNCY) and Biofrontera (NASDAQ:BFRI) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, dividends, institutional ownership, risk, earnings, profitability and analyst recommendations.

Analyst Recommendations

This is a breakdown of current recommendations for Unicycive Therapeutics and Biofrontera, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Unicycive Therapeutics	1	1	5	0	2.57
Biofrontera	1	1	1	0	2.00

Unicycive Therapeutics currently has a consensus price target of $18.75, suggesting a potential upside of 253.77%. Given Unicycive Therapeutics’ stronger consensus rating and higher probable upside, analysts plainly believe Unicycive Therapeutics is more favorable than Biofrontera.

Institutional & Insider Ownership

40.4% of Unicycive Therapeutics shares are owned by institutional investors. Comparatively, 10.1% of Biofrontera shares are owned by institutional investors. 6.0% of Unicycive Therapeutics shares are owned by insiders. Comparatively, 8.1% of Biofrontera shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Profitability

This table compares Unicycive Therapeutics and Biofrontera’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Unicycive Therapeutics	N/A	-91.50%	-61.47%
Biofrontera	-13.78%	-145.81%	-31.30%

Volatility and Risk

Unicycive Therapeutics has a beta of 1.79, meaning that its stock price is 79% more volatile than the S&P 500. Comparatively, Biofrontera has a beta of 0.83, meaning that its stock price is 17% less volatile than the S&P 500.

Earnings and Valuation

This table compares Unicycive Therapeutics and Biofrontera”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Unicycive Therapeutics	$680,000.00	217.07	-$26.56 million	($1.75)	-3.03
Biofrontera	$41.71 million	0.54	-$10.54 million	($0.45)	-3.36

Biofrontera has higher revenue and earnings than Unicycive Therapeutics. Biofrontera is trading at a lower price-to-earnings ratio than Unicycive Therapeutics, indicating that it is currently the more affordable of the two stocks.

Summary

Unicycive Therapeutics beats Biofrontera on 9 of the 14 factors compared between the two stocks.

About Unicycive Therapeutics

Unicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California.

About Biofrontera

Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a bacterial skin infection. It offers Ameluz, a prescription drug for use in combination with the RhodoLED lamp series, for photodynamic therapy for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp. The company also provides Xepi, a topical non-fluorinated quinolone that inhibits bacterial growth for the treatment of impetigo. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.